OTC Markets OTCQX - Delayed Quote USD

CSL Limited (CSLLY)

Compare
87.14 -2.46 (-2.75%)
As of 3:31:25 PM EST. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
14,690,000.00
14,690,000.00
13,174,000.00
10,493,100.00
10,265,300.00
Cost of Revenue
7,129,000.00
7,129,000.00
6,466,000.00
4,829,600.00
4,466,700.00
Gross Profit
7,561,000.00
7,561,000.00
6,708,000.00
5,663,500.00
5,798,600.00
Operating Expense
4,797,000.00
4,797,000.00
4,606,000.00
3,347,400.00
3,208,600.00
Operating Income
2,764,000.00
2,764,000.00
2,102,000.00
2,316,100.00
2,590,000.00
Net Non Operating Interest Income Expense
-437,000.00
-437,000.00
-406,000.00
-160,600.00
-166,900.00
Other Income Expense
110,000.00
110,000.00
136,000.00
81,600.00
44,700.00
Pretax Income
3,375,000.00
3,375,000.00
2,663,000.00
2,779,600.00
2,963,100.00
Tax Provision
661,000.00
661,000.00
419,000.00
524,900.00
588,100.00
Net Income Common Stockholders
2,642,000.00
2,642,000.00
2,194,000.00
2,254,700.00
2,375,000.00
Basic EPS
2.56
2.73
2.27
2.40
2.61
Diluted EPS
2.54
2.73
2.27
2.40
2.60
Basic Average Shares
965,137.97
966,021.70
964,346.30
937,509.71
909,731.21
Diluted Average Shares
970,507.16
969,541.28
968,653.42
939,458.33
911,708.25
Net Income from Continuing & Discontinued Operation
2,642,000.00
2,642,000.00
2,194,000.00
2,254,700.00
2,375,000.00
Normalized Income
2,642,000.00
2,642,000.00
2,194,000.00
2,254,700.00
2,375,000.00
Interest Income
39,000.00
39,000.00
38,000.00
17,400.00
3,900.00
Interest Expense
420,000.00
420,000.00
408,000.00
142,800.00
170,800.00
Net Interest Income
-437,000.00
-437,000.00
-406,000.00
-160,600.00
-166,900.00
EBIT
3,795,000.00
3,795,000.00
3,071,000.00
2,922,400.00
3,133,900.00
EBITDA
4,733,000.00
4,733,000.00
3,902,000.00
3,464,900.00
3,629,200.00
Reconciled Cost of Revenue
7,129,000.00
7,129,000.00
6,466,000.00
4,829,600.00
4,466,700.00
Reconciled Depreciation
938,000.00
938,000.00
831,000.00
542,500.00
495,300.00
Net Income from Continuing Operation Net Minority Interest
2,642,000.00
2,642,000.00
2,194,000.00
2,254,700.00
2,375,000.00
Normalized EBITDA
4,733,000.00
4,733,000.00
3,902,000.00
3,464,900.00
3,629,200.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
6/30/2021 - 12/29/2009

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BPMUF Basilea Pharmaceutica AG
52.83
0.00%
 
WXIBF WuXi Biologics (Cayman) Inc.
2.1900
+0.92%
 
GNMSF Genmab A/S
220.81
0.00%
 
22UA.MU BioNTech SE
120.00
+0.76%
 
UCBJF UCB SA
194.85
0.00%
 
UCBJY UCB SA
100.40
+0.23%
 
IVA Inventiva S.A.
2.1700
-2.25%
 
SLXN Silexion Therapeutics Corp
1.9300
-0.52%
 
GNFT Genfit S.A.
3.5940
-0.17%
 
207940.KS Samsung Biologics Co.,Ltd.
1,000,000.00
-0.60%